Cordyceps Sunshine Biotech Holdings (RAJAF) Liabilities and Shareholders Equity (2020 - 2025)

Cordyceps Sunshine Biotech Holdings' Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $4.7 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 0.73% year-over-year to $4.7 million; the TTM figure through Dec 2025 stood at $14.4 million (up 21.49% YoY), while the FY2025 annual figure was $4.7 million, up 0.73% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $4.7 million, up from $4.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $4.7 million in Q4 2025, with the low at $1.8 million in Q3 2023.
• The 5-year median for Liabilities and Shareholders Equity is $3.3 million (2021), against an average of $3.3 million.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity plunged 35.49% in 2022, then surged 59.24% in 2023.
• Cordyceps Sunshine Biotech Holdings' Liabilities and Shareholders Equity stood at $3.3 million in 2021, then plunged by 35.49% to $2.1 million in 2022, then jumped by 59.24% to $3.4 million in 2023, then surged by 37.95% to $4.6 million in 2024, then advanced by 0.73% to $4.7 million in 2025.
• Business Quant data shows RAJAF's Liabilities and Shareholders Equity at $4.7 million in Q4 2025, $4.6 million in Q4 2024, and $3.4 million in Q4 2023.